ADC Therapeutics SA Common Shares

IPO

ADC Therapeutics | Innovating Science. Inspiring Hope.

Public · Lausanne, Switzerland · Founded 2011 · $501.0M raised

Headquarters
Lausanne
Employees
201–500
Founded
2011
Business Model
B2B
Total Funding
$501.0M
Last Round
$276.0M Series EJun 2019
Rounds
6
Type
Public

About

ADC Therapeutics is a commercial-stage oncology company pioneering targeted antibody drug conjugate (ADC) therapies, with its FDA-approved ZYNLONTA (loncastuximab tesirine-lpyl) for relapsed or refractory large B-cell lymphoma. The company is advancing its ADC portfolio into earlier lines of hematologic cancers and solid tumors to address significant unmet medical needs.

Summary

ADC Therapeutics SA Common Shares is a Biotech company based in Lausanne, Switzerland, founded in 2011. It has raised $501.0M in total across 6 rounds, most recently a $276.0M Series E round in Jun 2019. Investors include AstraZeneca, Auven Therapeutics and Redmile Group.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

IPOMay 2020
$267.0M

Sign up to see all 7 rounds

Series A through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

ADC Therapeutics SA Common Shares on Indexed.vc
<a href="https://indexed.vc/companies/adc-therapeutics-sa-common-shares"><img src="https://indexed.vc/api/badge/company/adc-therapeutics-sa-common-shares" alt="ADC Therapeutics SA Common Shares on Indexed.vc" width="260" height="76" /></a>